Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Submission of Matters to a Vote of Security Holders

Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) Files An 8-K Submission of Matters to a Vote of Security Holders
Item 5.07 Submission of Matters to a Vote of Security Holders

Story continues below

On June 14, 2018, Bellicum Pharmaceuticals, Inc. (the “Company”) held its 2018 Annual Meeting of Stockholders (the "Annual Meeting"). As of April 17, 2018, the record date for the Annual Meeting, 33,656,045 shares of common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

A total of 28,260,180 shares of the Company's common stock were present at the meeting in person or by proxy, which represents approximately 83.97% of the shares of common stock outstanding as of the record date for the Annual Meeting.

Proposal 1. Election of Directors

The Company’s stockholders elected the three persons listed below as Class I Directors, each to serve until the Company’s 2021 Annual Meeting of Stockholders and until their successors are duly elected and qualified. The final voting results are as follows:

Name of Director Nominee:

Votes For

Votes Withheld

Broker Non-Votes

Frank B. McGuyer




Jon P. Stonehouse




Stephen R. Davis




Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm

The Company’s stockholders ratified the selection of Ernst& Young LLP by the Audit Committee of the Company's Board of Directors to serve as the Company’s independent registered public accounting firm for the fiscal year ending December31, 2018. The final voting results are as follows:

Votes For

Votes Against





About Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM)

Bellicum Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system. The Company is developing next-generation product candidates in the areas of cellular immunotherapy, including hematopoietic stem cell transplantation (HSCT), chimeric antigen receptors (CAR) T cells therapy and T-cell receptor (TCR) cell therapies. The Company’s product candidates include BPX-501, BPX-401, BPX-601 and BPX-701. BPX-501 is an adjunct T cell therapy for allogeneic hematopoietic stem cell transplantation. The Company’s CID-based technologies include CaspaCIDe, CIDeCAR and GoCAR-T.

An ad to help with our costs